EP1390028A2 - Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie - Google Patents

Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie

Info

Publication number
EP1390028A2
EP1390028A2 EP02738949A EP02738949A EP1390028A2 EP 1390028 A2 EP1390028 A2 EP 1390028A2 EP 02738949 A EP02738949 A EP 02738949A EP 02738949 A EP02738949 A EP 02738949A EP 1390028 A2 EP1390028 A2 EP 1390028A2
Authority
EP
European Patent Office
Prior art keywords
lipoic acid
use according
chemotherapy
preparation
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02738949A
Other languages
German (de)
English (en)
Inventor
Jeroen Johannes Maria Van Den Berg
Susanne Osanto
Robert Johan Joseph Hageman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to EP02738949A priority Critical patent/EP1390028A2/fr
Publication of EP1390028A2 publication Critical patent/EP1390028A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention is concerned with a method of suppressing the detrimental effects of chemotherapy and/or radiotherapy on a patient's health. More specifically the invention relates to a method comprising the administration of a special pharmaceutical or dietetic preparation containing lipoic acid and/or lipoic acid analogue in an effective amount to suppress the reduction in blood cell count resulting from chemotherapy and/or radiotherapy.
  • cancer is usually treated by surgically removing the tumour and/or chemotherapy and/or irradiation (radiotherapy).
  • radiationotherapy irradiation
  • the chemotherapy methods employed make use of agents that display antineoplastic, cytostatic, antibacterial and antiviral properties.
  • examples of chemotherapy agents that have found wide application are: alkylating agents such as cisplatin, tetrazines or nitrosourea substances, aziridines, musterd substances as well as antibiotics such doxorubicine, mitomycine and bleomycine.
  • anti-metabolites such as folic acid or nucleic acid analogues are used.
  • Chemotherapy agents usually exhibit very low therapeutic ratios (the ratio of toxic dose to effective dose), meaning that the extent to which a patient can be treated with such agents is limited by the toxicity level that is deemed acceptable.
  • doses of chemotherapy agent and/or irradiation often have to be reduced. Consequently the cancer treatment is prolonged, or worse, the chance of successful treatment is substantially reduced.
  • Lipoic acid (1,2 dithiolane-3-pentanoic acid or thioctic acid) is know as a pharmaceutical agent that may be used to reduce liver damage, to diminish the negative effects of a high doses of paracetamol or heavy metals.
  • Lipoic acid is also applied in a number of health preparations that mainly consist of herbal extracts and vitamines. In such preparations lipoic acid is incorporated because of its anti-oxidative properties, i.e. its ability to capture radicals in vitro.
  • Lipoic acid is also used in the treatment of diabetes, or to be more precise, in the treatment of insulin resistance and neuropathies. It is further known that lipoic acid plays an important role in oxidative decarboxylation processes in mammals.
  • WO 00/48594 describes a method for destroying tumour cells which method uses lipoic acid in combination with vitamin C. Suppression of reduction in blood cell count is nowhere mentioned in this patent application.
  • WO 99/06040 describes a method of reducing the incidence of cardiovascular disease and specific types of cancer in tobacco smokers using a combination of a tocotrienol and alpha-lipoc acid or tocotrienyl lipoate.
  • WO 99/55326 is concerned with a method of increasing glutathion levels in mammals by co-administering vitamin C and N-acetylcysteine. and a range of other components. Preparations for oral administration comprising alpha lipoic acid are described in the examples.
  • WO 98/57627 describes the combined use of carnitine and lipoic acid in a method of increasing the metabolic rate of aged cells without a concomitant increase in metabolic production of reactive oxygen species.
  • lipoic acid and its analogues can successfully be employed in a method of suppressing the reduction in blood cell count resulting from chemotherapy and/or radiotherapy, more particularly such a reduction in blood cell count resulting from chemotherapy and/or radiotherapy as applied in cancer treatment.
  • the method according to the present invention offers the advantage that it diminishes the negative (side) effects of chemotherapy and/or radiotherapy which negative effects more often than not have a dramatic effect on the patient's health.
  • the method additionally offers the advantage that it may enable continuation of chemotherapy/radiotherapy in cases where, in the absence of the present method, the therapy would have to be discontinued or dosages would have to be lowered because blood cell counts would otherwise be reduced to unacceptably low levels.
  • One aspect of the present invention is concerned with the use of lipoic acid and/or lipoic acid analogue in the manufacture of a pharmaceutical or dietetic preparation for use in a method of suppressing the reduction in blood cell count resulting from chemotherapy and/or radiotherapy, said method comprising the administration of lipoic acid and/or lipoic acid analogue in an amount effective to achieve a significant suppression of the reduction in cell count.
  • chemotherapy encompasses a method of treating patients by administering a antineoplastic, cytostatic, antibacterial and/or antiviral agent.
  • Lipoic acid exists in 2 isomer forms, i.e. R(+) lipoic acid and L(-) lipoic acid.
  • Lipoic acid is easily reduced to its disulfide form. Both the reduced and oxidised fom of lipoic acid can suitably he used in the method of the invention and are encompassed by the term "lipoic acid". Lipoic acid is quickly absorbed into the blood steam and equally fast removed therefrom. As a result bio-availability after oral administration is usually low. Particularly in fastened subjects it was found that less than 35% of the lipoic acid actually ingested became biologically available.
  • lipoic acid analogues are to be understood substances that either liberate lipoic acid in the body of the subject to whom the preparation is being administered. Usually this means that as a result of metabolic activity the lipoic acid is converted into lipoic acid or into a lipoic acid metabolite. Likewise the term lipoic acid analogue also encompasses substances that are structurally closely related and that show the same physiological functionality.
  • the present method may suitably be applied to vertebrate animals.
  • the method most suitable for application in mammals.
  • Most preferably the present method is used to suppress the negative effect of chemotherapy and/or radiotherapy on blood cell count in humans.
  • the method is advantageously used to suppress reduction in blood cell count resulting from cancer chemotherapy.
  • the amount of lipoic acid or lipoid acid analogue needed to achieve the desired suppression depends on a number of factors such as frequency of administration, the body weight of the subject, the type and dosage of chemotherapy agent employed, the duration of the chemotherapy, the physical condition of the subject etc. In general good results are obtained if the present method comprises administration of lipoic acid and/or lipoic acid analogue in a daily amount which is equivalent to 40-2000 mg R(+) lipoic acid.
  • blood cell count as used throughout this document, relates to the numbers of blood cells as determined by analytical methods well known in the art. Examples of blood cells which can suitably be measured by these techniques are: leukocytes, thrombocytes, lymphocytes and neutrophils (granulocytes).
  • the present method aims to reduce the reduction in cell count of at least one of the aforementioned types of blood cells.
  • the method suppresses the reduction of leukocyte count and or thrombocyte count and/or granulocyte count.
  • the method suppresses the reduction of leukocyte and/or thrombocyte count. Decreases in leukocyte levels are highly undesirable as these increase the risk of neutropene fever, infections, abscess etc. Decreases in thrombocyte count are associated with, for instance, an enhanced risk of blood loss.
  • the preparations used in the present process may suitably be administered before, during and/or after administration of the chemotherapy agent or before, during and/or after irradiation.
  • the preparations of the invention are administered after the chemotherapy agent has been administered or irradiation has occurred.
  • the preparation is preferably first administered no more than 48 hours, most preferably no more than 12 hours after said event. It is noted that it is also possible to combine chemotherapy agent and the present preparation into a single dosage units. Such an embodiment is encompassed by the present invention.
  • the method according to the present invention is effective in suppressing the reduction in blood cell count caused by a wide variety of chemotherapy agents.
  • chemotherapy agents include:
  • Alkylating agents e.g. aziridine, alkyl sulfonates, nitrosourea, tetrazines, cisplatin, carboplant, procarbazine, hexamethylmelamine, adozelesin
  • Antimetabolites e.g. folic acid analogues such as methorexate, antifolates such trimetrexate and tomudex, pyrimidine analogues, purine analogues and substituted urea substances such as hydroxy urea
  • Natural mitotic inhibitors e.g. vincristine, vinblastine, vindesine, vinorelabine
  • Podophyllum derivatives e.g. etoposide, teniposide
  • Taxanes (paclitaxel and docetaxel)
  • Enzymes such as asparaginase 9. Hormone and hormone antagonists (e.g. androgen, corticosteroids, estrogens, progestins, estrogen antagonists)
  • Hormone and hormone antagonists e.g. androgen, corticosteroids, estrogens, progestins, estrogen antagonists
  • Topoisomerase interactive agents e.g. idarubicin, epirubicin, mitoxantrone, losoxantrone, amsacrine, pyrazoloacridine
  • Retinoids e.g. all trans-retinoic acids, 13-cis retinoic acid, 9-cis retinoic acid, selective retinoid receptor agonists, fenretinide, 14-hydroxy-retro-retinol
  • Adrenal cortical suppressants such as mitotane
  • Steroid synthesis inhibitor such as aminoglutethimide
  • the present method is particularly effective in suppressing undesirable health effects resulting from a chemotherapy agent selected from the group consisting of alkylating agents and antimetabolites.
  • the pharmaceutical or dietetic preparation used in the present method may be administered in different ways, well-known in the art. It was found to be beneficial to administer the preparation orally.
  • Oral preparations for use in the present method advantageously contain a lipophylic carrier.
  • suitable lipophylic carriers are glycerides, phospholipids, cholesterol, glycerol, polyethylene glycol and mixtures thereof.
  • glycerides encompasses triglycerides (e.g. MCT oil), diglycerides and monoglycerides.
  • the lipophylic carrier is solid at ambient.
  • a suitable example of such a carrier is triglyceride fat containing a relatively high saturated fatty acid moiety.
  • the daily amount of the present preparation preferably contains less than 10 g of lipophylic carrier.
  • the oral preparation used in the present method is a sustained release preparation which releases most of the lipoic acid and lipoic acid analogue in or after the duodenum.
  • a sustained release preparation may suitably consist of microencapsules.
  • coated tablets, in particular tablets coated with an acid polymer, can advantageously be employed as sustained release preparation.
  • the lipoic acid analogue used is selected from the group consisting of pharmaceutically acceptable salts of lipoic acid, esters of lipoic acid, amino acid adducts of lipoic acid, peptide adducts of lipoic acid, lipoamide and mixtures thereof.
  • the esters of lipoic acid preferably comprise an acyl group with no more than 8 carbon atoms, preferably with less than 4 carbon atoms.
  • Examples of adducts of lipoic acid that can suitably be applied as lipoic acid analogues in accordance with the invention are adducts of lipoic acid and lysine and adducts of lipoic acid and lysine-rich peptides.
  • the method comprises the administration of the oxidised form of lipoic acid in an amount effective suppress the undesirable side effects. It was found that the oral administration of preparations containing oxidised lipoic acid is easier for patients suffering from mucositis. Mucositis is a side effect often encountered in patients undergoing chemotherapy.
  • the daily administered amount of oxidised lipoic acid is preferably kept below 10 mg/kg of bodyweight.
  • the method comprises additional administration of intact protein.
  • the combined use of lipoic acid and intact protein offers the additional advantage that the bad taste of lipoic acid is effectively masked.
  • the lipoic acid will cause less irritation to mucosa when co- administered with an adequate amount of intact protein.
  • the intact protein is administered in an amount effective to increase bio-availability of the lipoic acid or lipoic acid analogue by at least 10%.
  • the present method comprises administration of intact protein in a daily amount of at least 0.1 ⁇ moles, more preferably from 0.2 - 60 ⁇ moles.
  • intact protein encompasses polypeptides that comprise a relatively high fraction of basic amino acids such as lysine and arginine.
  • the lysine content of the intact protein is at least 8%.
  • the cystein content of the protein is preferably at least 2%.
  • the method comprises administration of lipoic acid and/or lipoic acid analogue and intact protein in a ratio of between 10:1 and 2,000:1 lipoic acid equivalent/ ⁇ mole intact protein.
  • the present method uses intact protein in the form of transferrin.
  • the transferrin used in the present method is selected from the group selected from the group consisting of lactoferrin, conalbumin, (lacto)ferricin and mixtures thereof.
  • the intact protein comprises metal and/or alkalimetal ions in an amount of at least 20%, more preferably at least 50% of the maximum number of metal and or alkalimetal ions that the protein may hold (the saturation level).
  • the aforementioned metal ions are preferably iron cations.
  • lactoferrin and conalbumin are suitably adminstered in daily amounts of 14-5000 mg, preferably 100-1000 mg.
  • (lacto)ferricin is suitably administered in daily amounts of 2-500 mg, preferably 10-100mg.
  • the combined use of lipoic acid and intact protein has the advantage that less lipoic acid needs to be administered to achieve the same level of suppression that would be observed if lipoic acid were administered in the absence of intact protein. This is relevant as lipoic acid is know to have in vitro cytotoxic effects at concentrations above 0.2 mM.
  • the method comprises administration of lipoic acid and/or lipoic acid analogue in a daily amount which is equivalent to 40-1000 mg R(+) lipoic acid. More preferably said dosage levels are within the range of 50-600 mg R(+) lipoic acid.
  • the lipoic acid used in the method of the invention may be obtained by organic synthesis, through natural production processes such as fermentation and enzymolysis, or by means of isolation and/or extraction from natural plant and animal materials.
  • natural raw materials are potato, spinach, eggs, yeast, heart and liver tissue.
  • the preparations used in the present method may also advantageously contain vitamin C, vitamin E, thiamine (e.g. as thiamine.HCl), flavonoids, carotenoids, zinc, manganese, magnesium, copper, selenium and/or coenzyme Q10. It is preferred to include thiamine in an amount of 0.5-5 mg per daily dose as this will further improve the overall efficacy of the present method.
  • thiamine e.g. as thiamine.HCl
  • the daily amount of magnesium administered in accordance with the present preparation preferably lies within the range of 50-400 mg, more preferably between 100 and 300 mg.
  • the preparation comprises vitamin E, vitamin C, N-acetyl cystein and zinc in the above mentioned amounts. Even more preferably the preparation also contains vitamin Bl in the above mentioned amount.
  • the invention also encompasses the use of functional analogues of the above components.
  • the minimum and maximum daily dosage can be established by determining which concentrations produce a functionally equivalent result to the minimum and maximum daily dosage cited for the parent component in the above table.
  • the dietetic preparations for use in the present method may suitably take the form of a beverage, a liquid (dilutable) concentrate, a water-soluble powder or granulate, or a candy bar.
  • the pharmaceutical preparation may take the form of a tablet, a powder, a capsule, a solution, an emulsion, a suspension or a suppository.
  • Another aspect of the invention relates to a pharmaceutical or dietetic preparation
  • a pharmaceutical or dietetic preparation comprising: a. lipoic acid and or lipoic acid analogue in an amount which is equivalent to 40-2000 mg R(+) lipoic acid, b. 0.2-60 ⁇ moles intact protein, c. 200-800 mg vitamin C, d. 100-500 mg vitamin E, e. 200- 1000 mg N-acetyl cystein f. 5-100 mg zinc.
  • the aforementioned preparation may advantageously and additionally comprise between 0.5 and 5 mg vitamin Bl.
  • Chemotherapy agents used in these treatments were: cisplatin and doxorubicine.
  • the effect of chemotherapy and radiotherapy on blood cells was monitored by measuring cell counts for neutrophilic granulocytes: leukocytes and thrombocytes at regular intervals.
  • a tablet for oral administration was prepared from the following components:
  • the above tablet can suitably be used in the method of the present invention.
  • a powder was prepared from the following components:
  • the powder was packed in sachets which can be dissolved in a liquid or pudding which may be administered/consumed in accordance with the method of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé permettant de supprimer les effets adverses de la chimiothérapie et/ou de la radiothérapie sur la santé d'un patient. L'invention concerne plus spécifiquement une méthode comprenant l'administration d'une préparation pharmaceutique ou diététique spéciale contenant de l'acide lipoïque et/ou un analogue d'acide lipoïque à raison d'une dose suffisante pour empêcher la réduction de la numération globulaire résultant d'une chimiothérapie et/ou d'une radiothérapie. L'invention concerne en outre une préparation pharmaceutique ou diététique comprenant : de l'acide lipoïque et/ou un analogue d'acide lipoïque à raison d'une quantité équivalente à 40-2000 mg d'acide lipoïque R(+), 0-60 νmoles de protéines intactes, 200-800 mg de vitamine C; 100-500 mg de vitamine D; 200-1000 mg de N-acétyl cystéine et 5-100 mg de zinc.
EP02738949A 2001-05-16 2002-05-16 Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie Withdrawn EP1390028A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02738949A EP1390028A2 (fr) 2001-05-16 2002-05-16 Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01201835A EP1258243A1 (fr) 2001-05-16 2001-05-16 L'acide lipoique pour la suppression des effets indésirables hématologiques dans la chimiothérapie et/ou radiothérapie
EP01201835 2001-05-16
EP02738949A EP1390028A2 (fr) 2001-05-16 2002-05-16 Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie
PCT/NL2002/000315 WO2002092077A2 (fr) 2001-05-16 2002-05-16 Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie

Publications (1)

Publication Number Publication Date
EP1390028A2 true EP1390028A2 (fr) 2004-02-25

Family

ID=8180319

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01201835A Withdrawn EP1258243A1 (fr) 2001-05-16 2001-05-16 L'acide lipoique pour la suppression des effets indésirables hématologiques dans la chimiothérapie et/ou radiothérapie
EP02738949A Withdrawn EP1390028A2 (fr) 2001-05-16 2002-05-16 Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01201835A Withdrawn EP1258243A1 (fr) 2001-05-16 2001-05-16 L'acide lipoique pour la suppression des effets indésirables hématologiques dans la chimiothérapie et/ou radiothérapie

Country Status (3)

Country Link
EP (2) EP1258243A1 (fr)
AU (1) AU2002311665A1 (fr)
WO (1) WO2002092077A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US8338397B2 (en) 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US7951845B2 (en) 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
CA2655331A1 (fr) * 2006-06-22 2007-12-27 Agennix Incorporated Lactoferrine en tant qu'agent radioprotecteur
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process
US9180088B2 (en) * 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
WO2010059245A2 (fr) * 2008-11-21 2010-05-27 The Johns Hopkins University Compositions et procédés pour traiter ou prévenir les lésions dues à un rayonnement
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159519A3 (fr) * 1984-03-29 1987-02-04 Asta-Werke Aktiengesellschaft Chemische Fabrik Utilisation de composés thio pour prévenir la chute des cheveux provoquée par des cytostatiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02092077A2 *

Also Published As

Publication number Publication date
WO2002092077A3 (fr) 2003-03-20
EP1258243A1 (fr) 2002-11-20
AU2002311665A1 (en) 2002-11-25
WO2002092077A2 (fr) 2002-11-21

Similar Documents

Publication Publication Date Title
US7226916B1 (en) Preparation for the prevention and/or treatment of vascular disorders
WO2002092077A2 (fr) Methode permettant de supprimer les effets hematologiques indesirables de la chimiotherapie et/ou de la radiotherapie
EP1919304B1 (fr) Compositions et methodes destinees a ameliorer l'integrite vasculaire fonctionnelle et la survie cellulaire et a reduire l'apoptose apres un episode ischemique dans le cerveau
US20200129463A1 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
EP1985307A2 (fr) Préparation pour la prévention et/ou le traitement des dépressions
US20210205334A1 (en) Methods and Composition for Increasing Muscle Protein Synthesis and/or Functional Strength in Mammals
WO2006032115A2 (fr) Composition contre des maladies cardio-vasculaires
WO2009057994A1 (fr) Dosage unitaire pour la santé cérébrale
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
JP4300753B2 (ja) 貧血抑制剤及び食欲抑制剤
JP2008509877A (ja) 通常、ビタミンｃ、マグネシウム、緑茶抽出物を含む心血管系疾患を抑制するための医薬調合物
JP2020503388A (ja) 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物
US20220362188A1 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
EP3842038A1 (fr) Formulation microencapsulée comprenant du fer et de la cysteine
JPH06247876A (ja) アルコール性肝障害軽減剤
WO2008037047A1 (fr) Composition et procédé pour l'accroissement de la masse musculaire maigre, la réduction de perte musculaire, l'accroissement de la force musculaire et l'amélioration de la performance athlétique
Houston Nutrition, nutraceuticals, vitamins, antioxidants, and minerals in prevention and treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090620